Hemogenyx Pharmaceuticals (LSE:HEMO) ROCE % : -74.58% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hemogenyx Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -74.58%.

Hemogenyx Pharmaceuticals ROCE % Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals ROCE % Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-97.13

-235.12

-55.52

-54.95

-108.16

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial												-35.05	-30.33	-86.09	-130.14	-74.58

Hemogenyx Pharmaceuticals ROCE % Calculation

Hemogenyx Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6.381	/	( ( (7.093 - 0.748)	+	(6.106 - 0.652) )	/ 2 )
	=	-6.381	/	( (6.345	+	5.454)	/ 2 )
	=	-6.381	/	5.8995
	=	-108.16 %

Hemogenyx Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-4.438	/	( ( (7.224 - 0.777)	+	(6.106 - 0.652) )	/ 2 )
	=	-4.438	/	( ( 6.447	+	5.454 )	/ 2 )
	=	-4.438	/	5.9505
	=	-74.58 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Hemogenyx Pharmaceuticals (LSE:HEMO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hemogenyx Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines